➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Baxter
Express Scripts
Dow
Boehringer Ingelheim

Last Updated: June 17, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Gossypol


Email this page to a colleague

« Back to Dashboard

What is the drug development status for Gossypol?

Gossypol is an investigational drug.

There have been 10 clinical trials for Gossypol. The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2013.

The most common disease conditions in clinical trials are Lung Neoplasms, Small Cell Lung Carcinoma, and Leukemia, Lymphocytic, Chronic, B-Cell. The leading clinical trial sponsors are National Cancer Institute (NCI), Mayo Clinic, and Third Military Medical University.

There is one US patent protecting this investigational drug and seven international patents.

Recent Clinical Trials for Gossypol
TitleSponsorPhase
R-(-)-Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple MyelomaNational Cancer Institute (NCI)Phase 1/Phase 2
R-(-)-Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple MyelomaMayo ClinicPhase 1/Phase 2
Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic LeukemiaNational Cancer Institute (NCI)Phase 1/Phase 2

See all Gossypol clinical trials

Clinical Trial Summary for Gossypol

Top disease conditions for Gossypol
Top clinical trial sponsors for Gossypol

See all Gossypol clinical trials

US Patents for Gossypol

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Gossypol   Get Started Free Heterocyclic compounds useful in the treatment of disease Epigen Biosciences, Inc. (San Diego, CA)   Get Started Free
Gossypol   Get Started Free Pyrazol-3-ones that activate pro-apoptotic BAX Dana-Farber Cancer Institute, Inc. (Boston, MA)   Get Started Free
Gossypol   Get Started Free Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders Dana-Farber Cancer Institute, Inc. (Boston, MA)   Get Started Free
Gossypol   Get Started Free Methods for sensitizing a quiescent cancer stem cell to a BCR-ABL inhibitor The Regents of the University of California (Oakland, CA)   Get Started Free
Gossypol   Get Started Free Methods and compositions for treating infection UNIVERSITY OF ROCHESTER (Rochester, NY) UNIVERSITY OF KANSAS (Lawrence, KS)   Get Started Free
Gossypol   Get Started Free Precise delivery of therapeutic agents to cell mitochondria for anti-cancer therapy University of Georgia Research Foundation Inc. (Athens, GA)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Gossypol

Drugname Country Document Number Estimated Expiration Related US Patent
Gossypol Australia AU2014232383 2033-03-15   Get Started Free
Gossypol Australia AU2019202731 2033-03-15   Get Started Free
Gossypol Brazil BR112015023267 2033-03-15   Get Started Free
Gossypol Canada CA2906931 2033-03-15   Get Started Free
Gossypol Canada CA3046894 2033-03-15   Get Started Free
Gossypol China CN105142635 2033-03-15   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
Moodys
McKesson
Colorcon
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.